1. Home
  2. ONL vs CUE Comparison

ONL vs CUE Comparison

Compare ONL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.44

Market Cap

165.4M

Sector

Real Estate

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$18.55

Market Cap

177.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
CUE
Founded
2021
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.4M
177.0M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
ONL
CUE
Price
$2.44
$18.55
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $88.00
AVG Volume (30 Days)
★ 470.1K
143.1K
Earning Date
11-05-2026
11-16-2026
Dividend Yield
★ 3.23%
N/A
EPS Growth
N/A
★ 61.11
EPS
★ 0.19
N/A
Revenue
★ $147,647,000.00
$27,466,000.00
Revenue This Year
$1.67
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
$13.05
★ N/A
Revenue Growth
N/A
★ 195.75
52 Week Low
$1.89
$0.17
52 Week High
$3.05
$45.50

Technical Indicators

Market Signals
Indicator
ONL
CUE
Relative Strength Index (RSI) 59.88 43.86
Support Level $2.40 $18.20
Resistance Level $2.59 $33.41
Average True Range (ATR) 0.12 1.86
MACD 0.05 0.49
Stochastic Oscillator 88.33 54.45

Price Performance

Historical Comparison
ONL
CUE

About ONL Orion Office REIT Inc.

Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Share on Social Networks: